Table 2.
Risk of bleeding associated with type of antidepressant in atrial fibrillation patients taking oral anticoagulants, unmatched sample, MarketScan®, 2007–2015
| TCA | SSRI | SNRI | SRI | Other | |
|---|---|---|---|---|---|
| No. events | 156 | 958 | 126 | 170 | 202 |
| Person-years | 5562 | 27895 | 4812 | 5207 | 5852 |
| Incidence rate per 100 person-years (95% CI) | 2.81 (2.38–3.28) | 3.43 (3.22–3.66) | 2.62 (2.18–3.12) | 3.27 (2.79–3.79) | 3.45 (2.99–3.96) |
| Hazard ratio (95% CI) | |||||
| Model 1a | 1 | 1.17 (0.99–1.38) | 0.94 (0.74–1.19) | 1.05 (0.84–1.30) | 1.09 (0.89–1.34) |
| Model 2b | 1 | 1.17 (0.99–1.39) | 0.93 (0.74–1.18) | 1.03 (0.83–1.28) | 1.09 (0.88–1.34) |
CI confidence interval, Other other antidepressants, SNRI serotonin/norepinephrine reuptake inhibitor, SRI serotonin reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TCA tricyclic antidepressant
aModel 1 was adjusted for age and sex
bModel 2 was adjusted for age, sex, HAS-BLED score, CHA2DS2-VASc score, alcohol use, comorbid conditions (heart failure, hypertension, diabetes, myocardial infarction, peripheral artery disease, kidney failure, stroke, bleeding, anemia, coagulopathy, cancer, mood disorder, cognitive impairment, chronic obstructive pulmonary disease, and liver disease) and other medications (antiplatelet, diuretic drugs, antiarrhythmic drugs, digoxin, angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, and lipid-lowering medications